Heidi Kakko
Angel Investor
Heidi Kakko is a Series A investor focused on Medical and Health Care. Heidi Kakko leads the Development Fund´s investment division by preparing the investments and developing the whole market.Heidi has been actively participating in financing and acquiring companies since 1995, she worked on business consultation and finance at the world`s biggest consultation company PricewaterhouseCoopers for more than 10years.Before joining the Development Fund, Heidi worked as an M&A Leader at an international investment company East Partners, focusing on the markets of Ukraine, Russia and Georgia. As an executive manager, Heidi has gained experience working at the biggest BTL agency in the Baltics as well as developing one of the first Estonian training companies into a business school.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Heidi Kakko invests in
Stages Heidi Kakko invests in
Countries Heidi Kakko invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $1.8M–$16M
Investment Focus
Industry
- Medical 1 (20%)
- Health Care 1 (20%)
- Therapeutics 1 (20%)
- Biotechnology 1 (20%)
- Manufacturing 1 (20%)
Stage
- Series A 2 (40%)
- Funding Round 2 (40%)
- Seed 1 (20%)
Country
- Norway 1 (20%)
- Estonia 1 (20%)
- Ireland 1 (20%)
- Switzerland 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nanordica Medical
|
Nanordica Medical is an Estonian medical technology company providing the first-line treatment for chronic wounds based on unique patented nanotechnology, a synergy of copper and silver in nanofibers that remove infection and support wound healing.Nanordica Medical launched a veterinary product Ravimus Vet for animal wounds(https://nanordica.com/ravimus.html) and is developing a first-in-class wound dressing for human hard-to-heal wounds like diabetic foot ulcers. They recently completed a clinical trial showing consistently better results in nearly all efficacy parameters observed among the patients treated with the Nanordica wound dressing than those treated with the commercially available silver ions-based active dressing. | $1.8M / Venture - Series Unknown / Jun 09, 2026 | |
|
Nanordica Medical
|
Nanordica Medical is an Estonian medical technology company providing the first-line treatment for chronic wounds based on unique patented nanotechnology, a synergy of copper and silver in nanofibers that remove infection and support wound healing.Nanordica Medical launched a veterinary product Ravimus Vet for animal wounds(https://nanordica.com/ravimus.html) and is developing a first-in-class wound dressing for human hard-to-heal wounds like diabetic foot ulcers. They recently completed a clinical trial showing consistently better results in nearly all efficacy parameters observed among the patients treated with the Nanordica wound dressing than those treated with the commercially available silver ions-based active dressing. | $402.7K / Seed / Jan 10, 2023 | |
Sensibel
|
Sensibel commercializes ultra-high-sensitivity MEMS microphones based on an optical MEMS technology. | $16.1M / Series A / Apr 25, 2022 | |
Positrigo
|
Positrigo is a company dedicated to the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. | $1.8M / Series A / Jul 30, 2021 | |
RemedyBio
|
RemedyBio is an immunology-focused discovery and development company based in Dublin, Ireland. It has pioneered a new approach to understanding the immune system and the discovery of new therapies. | $9.4M / Venture - Series Unknown / Jul 20, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Heidi Kakko invest in?
Heidi Kakko invests primarily in Medical, Health Care and Therapeutics startups, most often at Series A and Funding Round stage. Most of the 5 investments tracked by Shizune back companies in Norway. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Heidi Kakko's check size?
Heidi Kakko typically joins rounds of $1.8M–$16M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Heidi Kakko participates in.
How do I contact Heidi Kakko?
Public channels for Heidi Kakko include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Heidi Kakko last invest?
The most recent investment recorded for Heidi Kakko closed in Jun 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
